Recently, a role for increased STAT1 signaling in endocrine resistance was reported in studies that identified STAT1 as a potential mediator of endocrine resistance/sensitivity in BC and an appropriate STAT1 inhibitor could serve as a therapy in endocrine resistant BC (331, 337). This evidence concerns the gene STAT1 and breast cancer.